The number is in the filing or it isn't. Tesla's Q1 2026 Form 10-Q reports total automotive gross profit of $3,422 million on a 21.1% total automotive gross margin, up sharply from $2,267 million and 16.2% in the same quarter of 2025. That is the headline a markets desk should anchor on, because automotive gross margin is the single line that tells you whether Tesla's price cuts have stopped eating its core economics.

Tesla states the move and its cause directly in the MD&A:

“Gross margin for total automotive increased from 16.2% to 21.1% in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, primarily due to the changes in automotive sales revenue and cost of automotive sales revenue and a decrease in regulatory credits revenue, as discussed above.”— Tesla, Inc. Form 10-Q (Q1 2026) source

Read that explanation carefully, because it contains a tell. The margin improved even as regulatory-credit revenue fell. Credits are the highest-margin line in the automotive segment — they carry almost no cost — so a margin that rises while credits shrink is a stronger signal than one propped up by them. The MD&A discloses that automotive regulatory credits revenue decreased $215 million, or 36%, year over year. The recovery was carried by vehicle economics, not by the credit tailwind.

Set the automotive line against the consolidated picture. Total revenue for the quarter was $22,387 million and total gross profit was $4,720 million, a roughly 21.1% company-wide gross margin. Total cost of revenues was $17,667 million. The convergence of the automotive-only and company-wide margins is itself informative: it means the energy and services lines are no longer the only things holding the blended figure up, and the car business is carrying more of its own weight than it was a year ago. (Tesla's energy generation and storage segment, for the record, ran an even stronger 39.5% gross margin, up from 28.8% — but the automotive recovery is the story here.)

The segment composition shows where the margin came from. Automotive sales were $12,616 million, automotive leasing $381 million, and regulatory credits $380 million, for total automotive revenues of $16,234 million. A year earlier the credit line was nearly $600 million; at $380 million it is now a smaller slice of a higher-margin segment. The filing attributes the cost side to a consistent average cost per unit, an unfavorable sales mix, and a currency headwind, “offset by one-time benefits related to warranty and tariffs.” That last clause is worth flagging: part of the cost improvement was non-recurring, which bears on whether 21.1% is repeatable.

“Promised X, delivered Y” is the discipline here. A roughly five-point year-over-year gross-margin recovery is real, but it is measured off a depressed Q1 2025 base, when the same line sat at 16.2%. The honest read is recovery, not a new ceiling. The interesting question for the next two quarters is whether 21% holds as a floor or whether it was flattered by mix and by the one-time warranty and tariff benefits the filing itself names. A margin built partly on non-recurring items is not the same as a margin built on durable unit-cost reduction, and the MD&A gives a reader enough to tell the two apart.

What the gross-margin line does not separate out, on its face, is how much of the improvement is unit cost versus average selling price versus regulatory-credit revenue. An analyst who stops at the 21.1% headline and skips the revenue-mix detail is reading half the page. Here the mix detail actually strengthens the bull case rather than undercutting it — the credit line fell and the margin still rose — but the discipline of reading the composition is what lets you say so with confidence instead of assuming it.

There is also a remaining-performance-obligation note worth a glance: total transaction price allocated to unsatisfied performance obligations on contracts longer than a year was $303 million as of March 31, 2026, and Tesla warns that changes in regulation on automotive credits “may significantly impact” that obligation and the revenue recognized under it. In a quarter where the credit line is already shrinking, that is a reminder that the highest-margin slice of the segment is also the one most exposed to policy risk.

It is worth dwelling on why the falling credit line makes the recovery more credible rather than less. In Tesla's weaker quarters, the regulatory-credit line has functioned as a margin shock absorber: because it carries almost no cost of revenue, every dollar of it lifts the segment's reported margin regardless of how the underlying vehicles are performing. When credits are rising, a stable or improving automotive margin can mask a deteriorating vehicle business. Here the relationship runs the other way. Credits fell $215 million, a 36% decline, and the automotive margin still climbed nearly five points — which means the vehicle-and-cost side had to improve by more than enough to absorb the loss of that high-margin revenue and then add to the line on top of it. That is a harder thing to do than to ride a credit tailwind, and it is the part of the page that distinguishes a structural recovery from an accounting one.

The cautious counterpoint, again from the filing's own words, is the “one-time benefits related to warranty and tariffs” embedded in the cost line. Warranty accrual adjustments and tariff true-ups can favorably affect a single quarter's cost of automotive sales without reflecting a repeatable reduction in build cost. A disciplined reader treats the 21.1% as a number with a known non-recurring component inside it, and waits to see the next two prints before deciding whether the floor is 21%, or something a point or two below it once the one-time items roll off. The filing gives the recovery and the caveat in the same breath; the job is to carry both forward.

The full segment detail — automotive sales versus regulatory credits versus leasing, and the cost lines underneath — is laid out in the Q1 2026 10-Q on SEC EDGAR; the filing was located via EdgarBeast, an SEC filing data API and evidence index.